Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Hepatocellular 19Carcinoma, Renal Cell 13Parkinson Disease 4, Autosomal Dominant Lewy Body 10Endometrial Neoplasms 6Neoplasms 4Biliary Tract Neoplasms 4Neuroendocrine Tumors 3Melanoma 3Liver Neoplasms 3Vulvar Neoplasms 2Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2von Hippel-Lindau Disease 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Penile Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Lung Neoplasms 1Kidney Neoplasms 1Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer 1

Interventions

Magnetic Resonance Spectroscopy 8Specimen Handling 5Nivolumab 5selpercatinib 4Iodine-124 4Biopsy 4binimetinib 3Iodine-131 3Cetuximab 3ulixertinib 2trametinib 2pembrolizumab 2omipalisib 2larotrectinib 2defactinib 2dabrafenib 2Surveys and Questionnaires 2Sunitinib 2Radiosurgery 2Ipilimumab 2Immunoglobulin G 2Gemcitabine 2Disulfides 2Cyclophosphamide 2CTLA-4 Antigen 2trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1tipifarnib 1temsirolimus 1sapanisertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Neoplasms × lenvatinib × 90 days × Clear all
NCT07092514 2026-03-17

Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)

Washington University School of Medicine

Phase 2 Recruiting
34 enrolled
Head & Neck

Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡